2024
F12. CLINICALLY ACTIONABLE PHARMACOGENOMIC LANDSCAPE OF PSYCHOTROPICS IN QATAR
Velayutham D, Bastaki K, Irfan A, Abuhaliqa M, Ghuloum S, Azeem M, Pirmohamed M, Jithesh P. F12. CLINICALLY ACTIONABLE PHARMACOGENOMIC LANDSCAPE OF PSYCHOTROPICS IN QATAR. European Neuropsychopharmacology 2024, 87: 211. DOI: 10.1016/j.euroneuro.2024.08.423.Peer-Reviewed Original ResearchClinical Pharmacogenetics Implementation ConsortiumDutch Pharmacogenetics Working GroupGenetic variationClinical Pharmacogenetics Implementation Consortium recommendationsMetabolic phenotypeWhole-genome sequencing dataImplementing PGx testingGenome sequence dataIntegration of pharmacogenomicsPharmacogenetics Working GroupAnalysis of haplotypesQatari populationPGx testingSequence dataImplementation ConsortiumUltrarapid metabolizersPharmacogenetic testingPharmacokinetic genesGenetic variantsCase of antipsychoticsPsychotropic medication responseResponse to antidepressantsResponse phenotypesCase of haloperidolChoice of therapy
2019
Association of genes with phenotype in autism spectrum disorder
Nisar S, Hashem S, Bhat A, Syed N, Yadav S, Azeem M, Uddin S, Bagga P, Reddy R, Haris M. Association of genes with phenotype in autism spectrum disorder. Aging 2019, 11: 10742-10770. PMID: 31744938, PMCID: PMC6914398, DOI: 10.18632/aging.102473.Peer-Reviewed Original ResearchConceptsASD risk genesRisk genesNovel candidate genesAssociation of genesGene transcriptionGenetic pathwaysNeuronal activity modulationCandidate genesGenesGenetic variantsPathophysiology of ASDPathwayHeterogeneous neurodevelopmental disorderRegulation processesActivity modulationSynaptic plasticityNeurodevelopmental disordersTranscriptionIdentificationGeneticsPhenotypeRolePlasticityAutism spectrum disorderField of neuroscience